Pipeline
Pipeline
Muscle Weakness in Aging Adults
After about 35 years of age, muscle strength declines with age, typically at a rate of 1-1.5% per year for men and 0.5-2% per year for women. Several studies have shown that decreased muscle strength correlates with decreased mobility, increased mortality, and increased morbidity. Ridgeline's new therapeutic shows promise to maintain muscle strength during aging.
Obesity
Obesity is a poorly-controlled, global public health problem tied to many comorbidities. Current clinical best practices for first-line treatment are limited to diet modification (e.g., hypocaloric diet) and exercise, yet few individuals achieve their target weight loss through these means, let alone sustain it. We have a developed a drug that promotes rapid, robust, and persistent body weight and fat loss relative to diet switch alone.
Type 2 Diabetes
It's estimated that more than 460 million people worldwide have Type 2 Diabetes, and it's the ninth leading cause of death. Ridgeline Therapeutics has developed a unique approach to treat this ever-increasing diagnosis.
Chronic kidney disease
CKD causes a progressive and unrelenting decline in renal function, ultimately leading to end-stage kidney disease. CKD is one of the most prevalent chronic health issues facing older adults, impacting 35% of older Americans. Studies have demonstrated that our NNMT inhibitors can significantly reduce renal fibrosis and improve kidney function in CKD models.
Glioblastoma
Accounting for nearly 50% of all primary malignant brain tumors, this dangerous disease is notoriously aggressive. Average life expectancy post-diagnosis is often less than two years. Ridgeline's treatment targeting a key protein involved in metabolism aims to dramatically extend survival, and improve rates of remission.
Duchenne Muscular Dystrophy
Muscular dystrophies, like Duchenne's, are genetic conditions that result in muscle weakness and decreased mobility. Duchenne's in particular affects roughly 1 in every 3,500 male births worldwide. Ridgeline is developing small molecule therapeutics to help restore muscle strength and promote quality of life.